Marketing Rules & Restrictions

FDA's legal hook for compounded-drug advertising enforcement is FDCA §502(a) and §502(bb) (21 U.S.C. §352(a) and (bb)), which make a drug misbranded if its labeling or advertising is 'false or misleading in any particular' — the Supreme Court struck down the §503A advertising prohibition itself in Thompson v. Western States Medical Center, 535 U.S. 357 (2002) as an impermissible restriction on commercial speech.

On September 9, 2025, FDA and HHS publicly announced a broad enforcement initiative against telehealth compounded-drug advertising, with 'thousands of letters' warning pharmaceutical companies plus approximately 100 cease-and-desist letters and more than 50 formal warning letters — named recipients included Expert Aesthetics, The HCG Institute, Bioverse Inc., Elevate Your Wellness LLC, GLP-1 Solution, Tuyo Health Inc., Healthon Inc., SemaBio, Vitals RX, Fancy Meds, DirectMeds, JulyMD, Slendid, Try Nova, and eDrugstore.

FDA's September 2025 letters cited specific claims as misbranding: 'Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy,' 'Same active ingredient as Zepbound and Mounjaro,' 'generic versions,' 'clinically proven ingredients,' and 'With compounded semaglutide, you get the same trusted active ingredient as in brand-name medications.'

On March 3, 2026 FDA issued a second wave of 30 warning letters to telehealth companies for the same category of violations, identifying four flagged patterns: (1) implying compounded GLP-1 products are the same as FDA-approved versions, (2) suggesting equivalence to approved branded drugs, (3) obscuring product sourcing, and (4) advertising compounded products under telehealth-company brand names in ways that imply the telehealth firm itself is the compounder.

Eli Lilly filed four federal lawsuits in April 2025 against telehealth companies Fella Health, Willow Health, Henry Meds, and Mochi Health, alleging deceptive trade practices, false advertising, and unlawful corporate practice of medicine — specifically that defendants 'falsely advertise personalized options of tirzepatide drugs… when, in actuality, they are selling a standard, mass-produced compounded tirzepatide drug.'

Novo Nordisk sued Hims & Hers on February 9, 2026 for patent infringement over compounded semaglutide marketing; the case was voluntarily dismissed without prejudice as part of a March 2026 collaboration under which Hims & Hers agreed to offer Novo's branded Ozempic and Wegovy and cease advertising compounded GLP-1 'except where medically necessary' — Hims's Super Bowl GLP-1 ad parody was specifically flagged by FDA Commissioner Marty Makary in September 2025.

The FTC's December 2022 Health Products Compliance Guidance requires 'competent and reliable scientific evidence' for any health-related claim, generally meaning 'randomized, controlled human clinical testing' — animal/in vitro studies cannot substantiate human-effect claims, surveys cannot substantiate, and post-hoc 'p-hacking' analysis is rejected.

The FTC obtained a final order against telehealth weight-loss provider NextMed on December 3, 2025 (FTC v. NextMed; Robert Epstein and Frank Leonardo named individually), with $150,000 in monetary relief, for unsubstantiated weight-loss claims, fake testimonials, distorted consumer reviews, undisclosed costs ($138-188/month subscription that did not include the GLP-1 drug or required labs), and failure to obtain express informed consent before recurring debits.

The 2023-revised FTC Endorsement Guides (16 CFR Part 255, published July 26, 2023) expanded the definition of 'endorsement' to cover likeness depictions, tags, mentions, and 'no-comment' situations; tightened the 'clear and conspicuous' disclosure standard to require unavoidable disclosure in the same medium (visual + audible for video); and confirmed that consumer endorsements 'themselves are not competent and reliable scientific evidence' and disclaimers like 'results not typical' do not cure deception.

Meta's 2026 ad policy prohibits prescription-drug ads unless the advertiser is LegitScript-certified or has cleared Meta's internal review, only permits targeting to US/Canada/New Zealand audiences over 18, and 35 state attorneys general have pressured Meta on misleading weight-loss-drug ads.

Google Ads Healthcare & Medicines policy requires online pharmacies and telemedicine providers to hold LegitScript Healthcare Merchant Certification before targeting prescription-drug terms, restricts prescription-drug services advertising to US/Canada/New Zealand/Australia/India, and continues to prohibit promotion of unapproved pharmaceuticals; October 2025 update permits prescription-drug terms in ad text only in 'limited, non-promotional contexts.'

TikTok's healthcare and pharmaceuticals policy prohibits ads for prescription medications, online pharmacies, telehealth providers, therapy/mental-health consulting, etc. — making TikTok effectively closed for paid promotion of compounded peptide products.

X (Twitter) restricts the promotion of health and pharmaceutical products under its Healthcare Ads Policy and additionally prohibits the creation of custom audiences or conversion events based on sensitive health information; combined restriction makes X a difficult paid channel for compounded-peptide telehealth.

FDA's current statutory authority for compounded-drug advertising enforcement is the 2013 amendment to FDCA (codified at §502(bb), 21 U.S.C. §352(bb)). Bipartisan legislation S. 652 (Protecting Patients from Deceptive Drug Ads Act, Sens. Durbin/Marshall, February 2025) would expressly extend FDA jurisdiction over social-media influencers and telehealth companies.

California Business and Professions Code §651 makes it a misdemeanor for any licensed health professional to disseminate advertising likely 'to create false or unjustified expectations of favorable results,' including any photograph 'that does not accurately depict the results of the procedure being advertised' or that has been altered; use of a model photo without 'prominent location in easily readable type' disclosing model status is a violation.

Texas Medical Board Rule 164.3 (22 TAC §164.3) prohibits any advertisement 'in any way false, deceptive, or misleading' including testimonials with false statements or without disclaimers; photos of models or actors must be 'explicitly identified as models and not actual patients'; advertising that 'makes a representation likely to create an unjustified expectation about the results' is barred.

Florida Administrative Code 64B8-11.001 prohibits any advertisement 'in any way false, deceptive, or misleading,' including misrepresentation, partial disclosure creating false expectations, undelivered services, fees that don't represent actual charges — and requires the licensee's name to be 'clearly identif[ied] … as either a medical doctor (M.D.), physician assistant (P.A.), or anesthesiologist assistant (A.A.).'

New York Education Law §6530(27) defines professional misconduct as 'advertising or soliciting for patronage that is not in the public interest,' including any advertising that is 'false, fraudulent, deceptive, misleading, sensational, or flamboyant' or makes claims of 'professional superiority' the licensee cannot substantiate; testimonials in physician marketing materials are STRICTLY prohibited in New York even with patient consent and anonymity; licensees must maintain exact copy of each advertisement for one year.

HIPAA at 45 CFR §164.508(a)(3) requires a HIPAA-compliant written patient authorization before any use or disclosure of PHI for marketing, with limited exceptions only for face-to-face communications by the covered entity and 'promotional gift[s] of nominal value'; if marketing involves direct or indirect financial remuneration from a third party, the authorization must explicitly state so.

LegitScript Healthcare Merchant Certification (the de facto gatekeeper for Google, Meta, Microsoft, TikTok paid healthcare advertising) evaluates applicants against 9 standards; non-refundable application fee plus annual certification fee per website; ongoing monitoring continues after initial certification.

FDA placed BPC-157, TB-500 (Thymosin Beta-4 Fragment), and certain other peptides into Category 2 of the interim 503A bulks list on September 29, 2023, meaning FDA's official position is 'do not compound'; ipamorelin acetate was removed from Category 2 on September 27, 2024; FDA scheduled PCAC reconsideration July 23-24, 2026 — making any specific peptide-product marketing for these substances a heightened enforcement-trigger.

The compliant marketing posture for compounded peptide telehealth is to advertise the consultation, the condition category, and the patient experience — not the specific peptide or 'sameness' claim — with copy like 'personalized wellness programs for men over 40' clearing platform review while 'Buy sermorelin online' does not; advertising claiming compounded products are 'the same as' branded FDA-approved drugs has been specifically identified by FDA as misbranding.

Marketing creative line: product-named vs category/consultation framing

Use of patient testimonials and before/after photos

Influencer / affiliate marketing structure